SavedAdd your journal

Journals / Viral Hepatitis Journal / 2020 / Cilt: 26 - Sayı: 2

Evaluation of Treatment Results with Direct Acting Antiviral Drugs of Cirrhotic/Non-cirrhotic Chronic Liver Disease Caused by Hepatitis C Virus Genotype 1b Infection

Hepatit C Virüs Genotip 1b Kaynaklı Sirotik/Sirotik Olmayan Kronik Karaciğer Hastalığı Olgularında Doğrudan Etkili Antiviral İlaç Tedavisi Sonuçlarının Değerlendirilmesi

Birol TOPÇU
Mustafa DOĞAN
İlknur ERDEM
Rıtvan KARAALİ
Pages
43–48
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was a significantchange in serum albumin, alanine aminotransferase (ALT), aspartateaminotransferase (AST), gamma-glutamyl transferase (GGT) and alphafetoprotein (AFP) parameters in patients with compensated cirrhosisafter treatment, and total bilirubin, hemoglobin, ALT, AST, GGT, ALPand AFP parameters in the group without cirrhosis (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aimed to investigate the effect of treatmentwith direct-acting antivirals (DAAs) on the virological response and onthe some parameters used to evaluate liver function in cases withchronic liver disease due to hepatitis C virus (HCV) genotype 1b.Materials and Methods: This study included cases who were treatedwith DAAs after HCV genotype 1b infection.
📊
Key Findings & Data:HCV-RNA levels andbiochemical and hematological parameters measured at the beginningof treatment, 12th week and 52th week after the treatment weretransferred to the SPSS statistics software. model for end-stage liverdisease (MELD) and Child-Pugh scores were also calculated and addedto these data.Results: The study group consisted of a total of 102 patients, including33 (32%) males and 69 (68%) females.
💡
Conclusion & Impact:There was a significantchange in serum albumin, alanine aminotransferase (ALT), aspartateaminotransferase (AST), gamma-glutamyl transferase (GGT) and alphafetoprotein (AFP) parameters in patients with compensated cirrhosisafter treatment, and total bilirubin, hemoglobin, ALT, AST, GGT, ALPand AFP parameters in the group without cirrhosis (p
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aimed to investigate the effect of treatmentwith direct-acting antivirals (DAAs) on the virological response and onthe some parameters used to evaluate liver function in cases withchronic liver disease due to hepatitis C virus (HCV) genotype 1b.Materials and Methods: This study included cases who were treatedwith DAAs after HCV genotype 1b infection. HCV-RNA levels andbiochemical and hematological parameters measured at the beginningof treatment, 12th week and 52th week after the treatment weretransferred to the SPSS statistics software. model for end-stage liverdisease (MELD) and Child-Pugh scores were also calculated and addedto these data.Results: The study group consisted of a total of 102 patients, including33 (32%) males and 69 (68%) females. Compensated cirrhosis wasdetected in 26.5% of the patients (n=27). There was a significantchange in serum albumin, alanine aminotransferase (ALT), aspartateaminotransferase (AST), gamma-glutamyl transferase (GGT) and alphafetoprotein (AFP) parameters in patients with compensated cirrhosisafter treatment, and total bilirubin, hemoglobin, ALT, AST, GGT, ALPand AFP parameters in the group without cirrhosis (p

Özet

Amaç: Bu çalışmanın amacı, hepatit C virüs (HCV) genotip 1b’ye bağlı kronik karaciğer hastalığı gelişen olgularda, doğrudan etkili antiviral (DEA) ilaçlar ile yapılan tedavinin virolojik yanıt ve karaciğer fonksiyonlarını değerlendirmek için kullanılan bazı parametreler üzerine etkisinin irdelenmesidir. Gereç ve Yöntemler: Retrospektif bir çalışmadır. Bu çalışmaya HCV genotip 1b enfeksiyonu sonrası DEA ilaçlar ile tedavi edilen 18 yaşından büyük olgular dahil edildi. Tedavi başlangıcı, 12. ve 52. haftalara ait HCVRNA düzeyi, biyokimyasal ve hematolojik parametreler SPSS istatistik programına aktarıldı. Bu verilere, son dönem karaciğer hastalığı için model (MELD) ve Child-Pugh skorları da hesaplanarak eklendi. Bulgular: Çalışma grubu 33’ü (%32) erkek, 69’u (%68) kadın 102 hastadan oluşmaktadır. Hastaların %19’unda (n=20) kompanse siroz saptandı. Tedavi sonrası kompanse sirozu olan hastalarda serum albümin, alanin aminotransferaz (ALT), aspartate aminotransferas (AST), gama glutamil transferaz (GGT) ve alfa Fetoprotein (AFP) parametrelerinde, sirotik olmayan grupta ise total biluribin, hemoglobin, ALT, AST, GGT, ALP ve AFP parametrelerinde anlamlı değişiklik saptandı (p

🔖

Cite This Article

TOPÇU, B., DOĞAN, M., ERDEM, İ., KARAALİ, R. (2022). Evaluation of Treatment Results with Direct Acting Antiviral Drugs of Cirrhotic/Non-cirrhotic Chronic Liver Disease Caused by Hepatitis C Virus Genotype 1b Infection. Viral Hepatitis Journal, Cilt: 26 - Sayı: 2, 43–48. https://ajindex.com/articles/646356

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, Kaymakoglu S, Ergonul O. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21:1020-1026
  2. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004;24 Suppl 2:3-8
  3. Zarębska-Michaluk D, Piekarska A, Jaroszewicz J, Klapaczyński J, Mazur W, Krygier R, Belica-Wdowik T, Baka-Ćwierz B, Janczewska E, Pabjan P, Dobracka B, Lorenc B, Tudrujek-Zdunek M, Tomasiewicz K, Sitko M, Garlicki A, Czauż-Andrzejuk A, Citko J, Dybowska D, Halota W, Pawłowska M, Laurans Ł, Deroń Z, Buczyńska I, Simon K, Białkowska J, Tronina O, Flisiak R. Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/ Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. Adv Med Sci. 2019;65:12-17
  4. Aygen B, Demirtürk N, Türker N, Asan A, Eraksoy H, Gürbüz Y, İnan D, Keten D, Koçulu S, Öncü S, Özkaya D, Saltoğlu N, Sayan M, Süer K, Şener A, Tekin S, Tuna N, Yazıcı S. Kronik Hepatit C Virusu İnfeksiyonunun Yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu Uzlaşı Raporu-2017 Güncellemesi. Klimik Dergisi. 2017;30:Özel Sayı 2-36
  5. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease. Hepatology. 2018;68:827- 838
  6. Lobato CMO, Codes L, Silva GF, Souza AFM, Coelho HSM, Pedroso MLA, Parise ER, Lima LMSTB, Borba LA, Evangelista AS, Rezende REF, Cheinquer H, Kuniyoshi ASO, Aires RS, Quintela EHD, Mendes LSC, Nascimento FCV, Medeiros Filho JEM, Ferraz MLCG, Abdala E, Bittencourt PL; Members of the Brazilian Real-Life Study about HCV treatment; Members of the Brazilian Real-Life Study about HCV treatment. Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil. Ann Hepatol. 2019;18:849-854
  7. Wedemeyer H, Craxí A, Zuckerman E, Dieterich D, Flisiak R, Roberts SK, Pangerl A, Zhang Z, Martinez M, Bao Y, Calleja JL. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir± dasabuvir±ribavirin inpatients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. J Viral Hepat. 2017;24:936-943
  8. Abdulla M, Ali H, Nass H, Khamis J, AlQamish J. Efficacy of directacting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain. Hepat Med.